---
title: 'Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG
  5257 ancillary study'
date: '2021-08-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/34397689/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Zkrxt7ktlCbHBXEV3v65xxSnkSWNsJ1A6Fq3gBniKhGfIUslK&fc=20210907212339&ff=20210907212354&v=2.14.5
source: metablomics[MeSH Terms]
description: High cardiovascular disease risk in people living with HIV is partly
  attributed to antiretroviral therapy (ART). Lipid response to ART has been extensively
  studied, yet, little is known how small molecule lipids respond to Integrase inhibitor-based
  (INSTI-based) compared to Protease inhibitor-based (PI-based) ART regimens.Ancillary
  study to a phase 3, randomized, open-label trial [AIDS Clinical Trial Group A5257
  Study] in treatment-naive HIV-infected patients randomized in a 1:1:1 ratio ...
---
High cardiovascular disease risk in people living with HIV is partly attributed to antiretroviral therapy (ART). Lipid response to ART has been extensively studied, yet, little is known how small molecule lipids respond to Integrase inhibitor-based (INSTI-based) compared to Protease inhibitor-based (PI-based) ART regimens.Ancillary study to a phase 3, randomized, open-label trial [AIDS Clinical Trial Group A5257 Study] in treatment-naive HIV-infected patients randomized in a 1:1:1 ratio ...